Search
Browse
Statistics
Feeds

Selective depletion of autoreactive plasma cells as a novel strategy to treat acetylcholine receptor antibody-positive myasthenia gravis

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB
[thumbnail of Supporting Information]
Preview
PDF (Supporting Information) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
915kB

Item Type:Article
Title:Selective depletion of autoreactive plasma cells as a novel strategy to treat acetylcholine receptor antibody-positive myasthenia gravis
Creators Name:Khodadadi, Laleh, Puppe, Deborah, Cirillo, Dilara S., Martinez-Cingolani, Carolina, Klotsche, Jens, Pelz, Andreas, Kohler, Siegfried, Cheng, Qingyu, Lazaridis, Konstantinos, Fichtner, Michael, Pille, Jan, Kruglov, Andrey, Bondareva, Marina, Alexander, Tobias, Radbruch, Andreas, Meisel, Andreas and Hiepe, Falk
Abstract:Myasthenia gravis (MG) is a chronic autoimmune disease mediated by autoantibodies targeting the neuromuscular junction and leading to muscle weakness. Although there are autoantibodies of different specificities, most MG patients have autoantibodies directed against the nicotinic acetylcholine receptor (AChR), in particular against the extracellular domain of the α1 subunit (αECD), containing the main immunogenic region (MIR). Here, we demonstrate an original approach to selectively deplete plasma cells secreting autoantibodies targeting αECD. An antibody-mediated cytotoxicity-engager (ACE) consisting of an anti-hCD38-antibody conjugated to hAChR αECD (αECD) was used to deplete hAChR αECD-specific cells selectively in vivo. The reduction of pathogenic cells was accompanied by lower antibody titers, a reduction of MG disease score, protection of grip strength, and maintenance of body weight. Notably, antibody-secreting cells that are nonspecific for hAChR αECD were not affected. The resulting amelioration of MG pathology in ACE-treated animals highlights the decisive role of αECD-antibodies in the pathogenesis of MG and the clinical relevance of the novel therapeutic strategy.
Keywords:autoreactive Plasma Cells, Autoimmunity, Myasthenia Gravis, Selective Depletion, Animals, Mice
Source:European Journal of Immunology
ISSN:0014-2980
Publisher:Wiley
Volume:56
Number:4
Page Range:e70166
Date:April 2026
Official Publication:https://doi.org/10.1002/eji.70166
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library